DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

0090-9556/05/3308-1083-1096$20.00
DMD 33:1083-1096, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Riddick, D. S.
Right arrow Articles by Waxman, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Riddick, D. S.
Right arrow Articles by Waxman, D. J.
SYMPOSIUM REPORT

CANCER CHEMOTHERAPY AND DRUG METABOLISM

David S. Riddick, Chunja Lee, Shairoz Ramji, Edwin C. Chinje, Rachel L. Cowen, Kaye J. Williams, Adam V. Patterson, Ian J. Stratford, Charles S. Morrow, Alan J. Townsend, Youssef Jounaidi, Chong-Sheng Chen, Ting Su, Hong Lu, Pamela S. Schwartz, and David J. Waxman

Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada(D.S.R., C.L., S.R.); School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (E.C.C., R.L.C., K.J.W., I.J.S.); Auckland Cancer Society Research Center, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand (A.V.P.); Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, North Carolina (C.S.M., A.J.T.); and Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, Massachusetts(Y.J., C.-S.C., T.S., H.L., P.S.S., D.J.W.)

Abstract

Drug-metabolizing enzymes and drug transporters are key determinants of the pharmacokinetics and pharmacodynamics of many antineoplastic agents. Metabolism and transport influence the cytotoxic effects of antineoplastic agents in target tumor cells and normal host tissues. This article summarizes several state-of-the-art approaches to enhancing the effectiveness and safety of cancer therapy based on recent developments in our understanding of antineoplastic drug metabolism and transport. Advances in four interrelated research areas presented at a recent symposium sponsored by the Division for Drug Metabolism of the American Society for Pharmacology and Experimental Therapeutics (Experimental Biology 2004; Washington D.C., April 17–21, 2004) are discussed: 1) interactions of anthracyclines with drug-metabolizing enzymes; 2) use of hypoxia-selective gene-directed enzyme prodrug therapy (GDEPT) in combination with bioreductive prodrugs; 3) synergy between glutathione conjugation and conjugate efflux in conferring resistance to electrophilic toxins; and 4) use of cytochromes P450 as prodrug-activating enzymes in GDEPT strategies. A clear theme emerged from this symposium: drug metabolism and transport processes can be modulated and exploited in ways that may offer distinct therapeutic advantages in the management of patients with cancer.

Address correspondence to: David S. Riddick, Department of Pharmacology, Medical Sciences Building, University of Toronto, Toronto, Ontario, Canada M5S 1A8. E-mail: david.riddick{at}utoronto.ca




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
C. Fang, J. Gu, F. Xie, M. Behr, W. Yang, E. D. Abel, and X. Ding
Deletion of the NADPH-Cytochrome P450 Reductase Gene in Cardiomyocytes Does Not Protect Mice against Doxorubicin-Mediated Acute Cardiac Toxicity
Drug Metab. Dispos., August 1, 2008; 36(8): 1722 - 1728.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.